Categories: The Charlton Centre

Evusheld: who is eligible?

We have received questions regarding Evusheld as a pre-exposure preventative treatment for COVID-19. Evusheld is given as two intramuscular injections. This is only being supplied and administered at select clinic sites such as cancer and transplant centers due to the limited criteria for its use.

Evusheld is currently available in Ontario only to select immunocompromised patients, including:

• Solid organ transplant recipients
• Stem cell transplant recipients
• CAR-T cell therapy recipients
• Other hematologic cancer patients undergoing treatment

Currently,  this means that patients receiving advanced therapies for autoimmune conditions are not included in the eligible list.

Please see the Government of Ontario document here for more information.

Carolyn Whiskin is the Pharmacy Manager for Charlton Health. Carolyn specializes in the treatment of autoimmune diseases, pharmaceutical compounding, women’s health, pain, and smoking cessation. Carolyn has won provincial and national awards for her commitment to patient care and public service.

admin

Share
Published by
admin

Recent Posts

Happy Back-to-School!

This week, many will return to school, and it's no secret that the back-to-school season…

1 week ago

Staying Hydrated in the Summer

Staying well hydrated is important in every season, but it becomes especially crucial during thesummer.…

3 weeks ago

World Hepatitis Day

Last week, on July 28th, we observed World Hepatitis Day, a day dedicated to raising…

1 month ago

Traveling This Summer with Biologics? Here’s What You Need to Know

Summer is a great time to get out and see new sights. Whether you're planning…

2 months ago

Summer Sun Safety

Now that the warmer weather is here, many of us are spending more time enjoying…

2 months ago

New Biosimilars of Xolair and Actemra Now Available: Omlyclo and Tyenne

Biosimilars are becoming more common in Canada, offering patients trusted alternatives to the originator biologic medication. Biosimilars…

3 months ago